project id: TCGA-PRAD; case submitter id: TCGA-EJ-A6RA; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.15; rna integrity number: 7.6; age at index: 70; days to birth: -25679; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1942; age at diagnosis: 25679; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 353.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 213; initial weight: 250.0; sample id: 393b1df6-0029-4a6c-9581-d2af70e8615c; sample submitter id: TCGA-EJ-A6RA-01A; portion id: a5ca16e1-2798-4d81-bb8a-01a16c1b755c; portion submitter id: TCGA-EJ-A6RA-01A-11; slide id: 5af20b4d-acb4-491a-8e89-388af20c5c19; slide submitter id: TCGA-EJ-A6RA-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 30.0; percent stromal cells: 10.0; percent tumor cells: 60.0; percent tumor nuclei: 80.0; section location: TOP;